This company listing is no longer active
Medesis Pharma (ALMDP) Stock Overview
Operates as a biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ALMDP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Medesis Pharma S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.35 |
| 52 Week High | €2.00 |
| 52 Week Low | €0.30 |
| Beta | 0.18 |
| 1 Month Change | 0% |
| 3 Month Change | -12.94% |
| 1 Year Change | -63.92% |
| 3 Year Change | -89.71% |
| 5 Year Change | n/a |
| Change since IPO | -96.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| ALMDP | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | 1.4% |
| 1Y | -63.9% | 292.1% | 0.09% |
Return vs Industry: ALMDP underperformed the French Biotechs industry which returned -32.3% over the past year.
Return vs Market: ALMDP underperformed the French Market which returned -6% over the past year.
Price Volatility
| ALMDP volatility | |
|---|---|
| ALMDP Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 11.4% |
| 10% least volatile stocks in FR Market | 2.4% |
Stable Share Price: ALMDP has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: ALMDP's weekly volatility has decreased from 14% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 10 | Jean-Claude Maurel | www.medesispharma.com |
Medesis Pharma S.A. operates as a biopharmaceutical company. The company’s products include NanoLithium (NP03) for the treatment of Alzheimer’s disease; NanosiRNA HD and NanoP42T to treat Huntington’s disease; NanoLithium for the prevention and treatment of psychiatric disorders; NanoManganese (NP02), a radiation protection drug; and NU01 plutonium decorporation and NU02 cesium decorporation nuclear drugs. It also develops oncology drugs, including NanosiRNA IFNAR and NanoManganese Radiotherapy Glioblastoma.
Medesis Pharma S.A. Fundamentals Summary
| ALMDP fundamental statistics | |
|---|---|
| Market cap | €1.77m |
| Earnings (TTM) | -€3.13m |
| Revenue (TTM) | €63.64k |
Is ALMDP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMDP income statement (TTM) | |
|---|---|
| Revenue | €63.64k |
| Cost of Revenue | €2.13m |
| Gross Profit | -€2.07m |
| Other Expenses | €1.07m |
| Earnings | -€3.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.62 |
| Gross Margin | -3,244.94% |
| Net Profit Margin | -4,924.73% |
| Debt/Equity Ratio | -64.7% |
How did ALMDP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/16 12:28 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medesis Pharma S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.